Illumina (NASDAQ:ILMN) Price Target Increased to $128.00 by Analysts at Robert W. Baird

Illumina (NASDAQ:ILMN) had its price target raised by Robert W. Baird from $125.00 to $128.00 in a research report sent to investors on Friday, Benzinga reports. Robert W. Baird currently has a neutral rating on the life sciences company’s stock.

Several other research analysts have also recently weighed in on ILMN. Barclays lifted their price target on shares of Illumina from $85.00 to $100.00 and gave the stock an underweight rating in a research note on Wednesday, April 10th. Stephens reaffirmed an overweight rating and set a $170.00 price target on shares of Illumina in a report on Wednesday, April 10th. OTR Global reissued a mixed rating on shares of Illumina in a research note on Wednesday, March 20th. TD Cowen cut shares of Illumina from an outperform rating to a market perform rating and set a $144.00 target price on the stock. in a research note on Thursday, January 4th. Finally, HSBC downgraded shares of Illumina from a buy rating to a hold rating in a report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of Hold and a consensus target price of $165.10.

Illumina Stock Performance

Shares of NASDAQ ILMN traded down $6.06 during midday trading on Friday, hitting $117.93. 2,987,105 shares of the stock traded hands, compared to its average volume of 1,375,095. The firm has a market capitalization of $18.78 billion, a P/E ratio of -14.47 and a beta of 1.20. Illumina has a one year low of $89.00 and a one year high of $213.91. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a 50-day moving average of $130.03 and a two-hundred day moving average of $127.02.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a positive return on equity of 2.28% and a negative net margin of 28.71%. Illumina’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.08 earnings per share. On average, equities analysts forecast that Illumina will post 0.91 EPS for the current fiscal year.

Insider Activity at Illumina

In other Illumina news, CEO Jacob Thaysen acquired 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was acquired at an average cost of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.17% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bouvel Investment Partners LLC lifted its stake in shares of Illumina by 1.3% in the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock valued at $899,000 after purchasing an additional 84 shares during the last quarter. STF Management LP lifted its position in Illumina by 3.5% in the fourth quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock worth $368,000 after buying an additional 90 shares during the last quarter. Global Retirement Partners LLC boosted its stake in Illumina by 12.3% during the first quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock worth $118,000 after buying an additional 94 shares during the period. Gulf International Bank UK Ltd increased its position in Illumina by 0.7% during the first quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock valued at $1,862,000 after acquiring an additional 98 shares during the last quarter. Finally, Clear Creek Financial Management LLC raised its stake in shares of Illumina by 6.3% in the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.